----
Current ValuationThe current P/E ratio is 15.36, above the reasonable range, cheaper than 15.87% of the time in the past 5 years, and the industry ranks 9/74, the industry Median --.
15.36xP/E
$41.62Stock price
$2.71Earnings per share
15.36xP/E
Stock price$41.62Earnings per share$2.71
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 10.46x
- Typical range
- -2.68x–14.71x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
CIUSCigna | 12.63x | 11.91% | $81.02B |
FMSUSFresenius Medical Care | 11.42x | 27.29% | $12.41B |
DVAUSDaVita | 13.20x | 48.02% | $11.19B |
AVAHUSAveanna Healthcare | 10.13x | 31.53% | $2.78B |
MDUSPediatrix Medical | 13.05x | 1.36% | $2.28B |
AMNUSAMN Healthcare Services | 15.36x | 174.65% | $1.61B |
SBCUSSBC Medical | 11.45x | 6.50% | $561.54M |
SRTAUSStrata Critical Medical | 10.32x | 61.46% | $414.91M |
NIVFUSNewGenIvf | 1.99x | 97.79% | $2.23M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
